Memantine add on to citalopram in elderly pa tients with depression: A double-blind placebo-controlled study

Journal of Research in Medical Sciences

Volumn 19, Issue 6, 2014, Pages 525-530

  Omranifard, Victoria ^a   Shirzadi, Elham ^a   Samandari, Saeid ^a   Afshar, Hamid ^b   Maracy, Mohammad Reza ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Depression; Geriatric; Memantine; Quality of life

Indexed keywords

CITALOPRAM; MEMANTINE; PLACEBO;

ADD ON THERAPY; AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GERIATRIC DEPRESSION SCALE; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM;

EID: 84904675208     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Michaud CM, Murray CJ, Bloom BR. Burden of disease - Implications for future research. JAMA 2001;285:535-9.
2. Burden of mental and behavioral disorders. In: Murthy RS, editor. The World Health Report 2001. Mental Health: New Understanding, New Hope. Geneva, Switzerland: WHO; 2001. 24Y29.
3. Rangaswamy SM. The World Health Organization. Geneva: Switzerland. World Health Report: Mental Health: New understanding New Hope; 2001.
4. Stordal E, Bjartveit Kruger M, Dahl NH, Kruger Q, Mykletun A, DahI AA. Depression in relation to age and gender in the general population: The Nord-Trondelag Health Study (HUNT). Acta Psychiatr Scand 2001;104:210-6.
5. Namadian M, Ghobadi S, editors. Evaluation of mental status old age s Zanjan on 2001. Tehran: Ashena press; 2006. Persian.
6. Barua A, Ghosh MK, Kar N, Basilio MA. Socio-demographic factors of geriatric depression. Indian J Psychol Med 2010;32:87-92.
7. Katon WJ, Lin E, Russo J, Unützer J. Increased medical costs of a population-based sample of depressed elderly patients. Arch Gen Psychiatry 2003;60:897-903.
8. Akiskal HS. Comprehensive textbook of psychiatry. In: Sadock BJ, Sadock VA, editors. Mood disorders: Historical introduction and conceptual overview. Philadelphia: Williams and Willkins; 2005. p. 1559-27.
9. Delgado PL. Depression: The case for a monoamine deficiency. J Clin Psychiatry 2000;61:7-11.
10. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: A metaanalysis. Can J Psychiatry 1996;41:613-6.
11. Bhalla RK, BuĴer MA, Becker JT, Houck PR, Snitz BE, Lopez OL, et al. PaĴ erns of mild cognitive impairment aǦ er treatment of deoression in the elderly. AM J Geriatr psychiatry 2009;17:308-16.
12. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009;61:105-23.
13. Maeng S, Zarate CA Jr. The role of glutamate in mood disorders: Results from the ketemin in Major depressive study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007;9:467-74.
14. Kiss JP, Szasz BK, Fodor L, Mike A, Lenkey N, Kurkó D, et al. GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine. Neurochem Int 2012;60:170-6.
15. Ates-Alagoz Z, Adejare A. NMDA Receptor Antagonists for Treatment of Depression. Pharmaceuticals (Basel) 2013;6:480-99.
16. Hjerrild S, Bjerre J, Pedersen RH, Videbech P. Ketaminefor treatment of acute depression. Ugeskr Laeger 2013;175:2090-3.
17. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006;163:153-5.
18. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007;30:136-44.
19. Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial. J Affect Disord 2012;136:163-6.
20. Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Adv Psychiatr Treat 2002;8:189-97.
21. Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence. CNS Drugs 2012;26:663-90.
22. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009;123:143-50.
23. Sargolzaee MR, Fayyazi Bordbar MR, Samari AA, Shakiba M. The comparison of the efficacy of citrus fragrance and fluoxetine in the treatment of major depressive disorder. J Ofoghe-Danesh 2004;10:43-8.
24. Malakouti SK, Fatollahi P, Mirabzadeh A, Salavati M, Zandi T. Reliability, validity and factor structure of the GDS-15 in Iranian elderly. Int J Geriatr Psychiatry 2006;21:588-93.
25. Nedjat S, Montazeri A, Holakouie K, Mohammad K, Majdzadeh R. Psychometric properties of the Iranian interview-administered version of the World Health Organization's Quality of Life Questionnaire (WHOQOL-BREF): A population-based study. BMC Health Serv Res 2008;8:61.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
27. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 2010;176:870-80.
28. Apler A. Citalopram for major depressive disorder in adults: A systematic review and meta-analysis of published placebo- controlled trials. BMJ Open 2011;1:e000106.
29. Krystal JH. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants. Arch Gen Psychiatry 2010;67:1110-1.
30. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D- aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64.
31. Yilmaz A, Schulz D, Aksoy A, Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002;71:341-4.
32. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4.
33. Bolshakov KV, Gmiro VE, Tikhonov DB, Magazanik LG. Determinants of trap-ping block of N-methyl-D-aspartate receptor channels. J Neurochem 2003;87:56-65.
34. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999;38:735-67.
35. Lenze EJ, Skidmore ER, Begley AE, Newcomer JW, BuĴers MA, Whyte EM. Memantine for late-life depression and apathy aǦer a disabling medical event: A 12-week, double-blind placebo- controlled pilot study. Int J Geriatr Psychiatry 2012;27:974-80.